Virios Therapeutics (NASDAQ:VIRI) Stock Price Up 4.1% - What's Next?

Key Points

• Virios Therapeutics shares increased by 4.1% during trading, reaching a high of $5.15 before closing at $5.01.
• The company has a market cap of $96.48 million and is focused on developing antiviral therapies, particularly for fibromyalgia with its lead candidate IMC-1.
• Despite the rise in stock price, the trading volume was significantly lower, with only about 30,896 shares traded compared to an average daily volume of 1,049,645 shares.

Virios Therapeutics, Inc. (NASDAQ:VIRI - ) shares rose 4.1% during trading on Monday . The company traded as high as $5.15 and last traded at $5.01. Approximately 30,896 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 1,049,645 shares. The stock had previously closed at $4.81.

Virios Therapeutics Price Performance

The business has a 50-day simple moving average of $4.87 and a 200 day simple moving average of $5.07. The firm has a market cap of $96.48 million, a PE ratio of -18.56 and a beta of 1.58.

About Virios Therapeutics

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.